XE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
XE is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong strategic support and multiple bullish analyst initiations, but the current setup is still too speculative: the company is pre-revenue, just reported a wide Q1 loss, and the share price fell sharply to 21 after the latest news. Since there is no AI Stock Picker or SwingMax buy signal, and the current price action is weak, I would not call this an immediate buy. For an impatient investor, the better choice is to wait rather than chase it here.
Current price is 21 with a sharp regular-session decline of 11.16%, which signals strong near-term selling pressure. Pre-market is essentially flat at -0.04%, so there is no meaningful rebound confirmation yet. No dedicated stock trend data was provided, but the price action around the earnings release is clearly bearish in the short term. Overall, the technical picture is weak right now, even though the long-term story remains attractive.
["Multiple bullish analyst initiations on 2026-05-19 to 2026-05-20, including Overweight/Buy ratings and price targets mostly in the $35-$57 range.", "Cantor Fitzgerald called X-Energy one of the most strategically positioned companies in advanced nuclear.", "TD Cowen, Guggenheim, Morgan Stanley, UBS, and JPMorgan all highlighted strong technology, partnerships, backlog, and vertical integration.", "Revenue in Q1 2026 grew 108.7%-109% year over year, showing rapid commercial traction.", "The company raised about $1.1 billion through its IPO, improving balance-sheet flexibility.", "Options data leans bullish with put-call ratios below 1."]
["Q1 2026 revenue of $43.42 million missed expectations by $24.45 million.", "Net loss widened to $166.2 million in Q1 2026, reinforcing that the business is still deeply unprofitable.", "The stock dropped 11.16% in the regular session, showing clear post-news selling pressure.", "Jefferies is only Hold with a $28 target, showing not all analysts are fully bullish.", "The company is still pre-revenue/early-commercial in nature, which makes long-term execution risk high.", "No recent congress trading data or influential insider/politician buying support was provided."]
Latest quarter: Q1 2026. Revenue was $43.42 million, up 108.7% year over year, which is strong growth, but it missed analyst expectations significantly. The net loss widened to $166.2 million, so while growth is accelerating, profitability remains distant and cash burn is still substantial. For a long-term investor, the growth trend is positive, but the latest quarter shows the business is still early and execution-sensitive.
Analyst sentiment is broadly bullish. Recent initiations include Cantor Fitzgerald Overweight $38, TD Cowen Buy $35, Guggenheim Buy $57, Morgan Stanley Overweight $41, UBS Buy $40, and JPMorgan Overweight $38. Wolfe was more neutral with Peer Perform and a $27-$37 fair value range, while Jefferies was Hold at $28, creating a minority cautious view. Overall Wall Street pros are constructive on the stock’s strategic positioning, technology, backlog, and partnerships, but the more cautious camp points to a balanced risk/reward at current levels.
